Diagnosis: Growth potential
We are now more than halfway through the year, and for many people, this is the time when they start feeling age creep up on them a little more. Whether it’s aching joints, keeping a closer eye on health, or simply becoming more aware of the importance of quality healthcare, it’s a reminder that medical innovation remains one of the most important investment themes in the market today.
For investors, healthcare isn’t just about improving lives. It is also a sector that consistently generates opportunities through clinical breakthroughs, regulatory milestones, and emerging technologies. Three companies that have recently captured investor attention, let’s get into it.
This article is a journalistic opinion piece that has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Positive Phase II dementia trial results
MediPharm Labs Corp. (TSX: LABS, Forum) continues to strengthen its position as a leader in precision cannabinoid pharmaceuticals after announcing encouraging results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial. The findings were presented at the Alzheimer’s Association International Conference (AAIC) in London on July 14, 2026.
The study focused on a particularly challenging healthcare problem: agitation in patients with advanced dementia. According to the Alzheimer’s Clinical Trial Consortium, roughly half of patients diagnosed with Alzheimer’s disease or other dementias ultimately receive hospice care, and more than 70 per cent are prescribed psychiatric medications to manage agitation. These treatments often carry significant side effects that can reduce the quality of life for both patients and caregivers.
The randomized, double-blind, placebo-controlled trial met its primary endpoint, demonstrating statistically significant improvements in agitation symptoms compared with placebo. Benefits were observed as early as two weeks after treatment began and remained consistent throughout the 12-week study period. Additional findings from the open-label extension suggested that patients continued to benefit over time.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
Beyond the clinical success, the results highlight MediPharm’s pharmaceutical development capabilities. The company developed and manufactured the proprietary oral cannabinoid formulation used in the study and supplied materials into the United States through its regulated international distribution network. MediPharm also retains ownership of the formulation and associated intellectual property rights, giving it several avenues for future value creation through patent protection, regulatory submissions, and additional development opportunities.
For investors, the announcement represents an important validation of MediPharm’s strategy to move beyond cannabinoid production and further into pharmaceutical-grade therapeutics. Positive clinical data in an area of significant unmet medical need could potentially open new commercial and partnership opportunities in the growing neurodegenerative disease market.
Advancing toward potential registration pathway
Another Canadian biotechnology company generating excitement is Oncolytics Biotech Inc. (NASDAQ: ONCY, Forum), which provided an important clinical and regulatory update regarding its ongoing REO 033 study.
The trial is evaluating pelareorep, the company’s investigational immunotherapy, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with RAS-mutant, microsatellite stable metastatic colorectal cancer. This indication represents a significant unmet need within oncology, making positive clinical outcomes particularly meaningful.
REO 033 builds on the earlier REO 022 study, which delivered results that exceeded historical benchmarks across several key measures, including progression-free survival, overall survival, objective response rate, and duration of response. Those results helped pelareorep earn Fast Track designation from the U.S. Food and Drug Administration.
Operationally, the company appears to be making strong progress. Approximately half of the planned clinical sites are expected to be activated by the end of July, while the remaining sites are anticipated to come online by the end of August. More than 20 patients have already been pre-identified across participating centers, supporting expectations for accelerated enrollment during the second half of 2026.
Perhaps the most significant development for investors is the company’s upcoming Type D meeting with the FDA scheduled for the first half of August. During the meeting, Oncolytics plans to discuss expanding REO 033 through a registration-directed Part B study. The proposed design would increase enrollment and incorporate blinded independent central review while preserving many of the efficiencies established in the current trial.
If the FDA supports the proposed pathway, Oncolytics could potentially generate both accelerated approval and traditional approval data within a single clinical program. Such an approach may reduce timelines and costs while keeping development momentum intact. The company also expects to provide an initial tumor response update before the end of 2026, giving investors another potential catalyst to watch.
For shareholders, the combination of promising prior data, accelerating enrollment, regulatory engagement, and upcoming clinical updates creates a compelling series of milestones that could significantly influence the company’s valuation over the next several quarters.
Expanding into pharmaceutical security infrastructure
While not a traditional biotech company, Xtract One Technologies (TSX: XTRA, Forum) has made healthcare-related headlines through a significant commercial win that showcases the growing importance of security technology within pharmaceutical and life sciences facilities.
The company recently announced that its Xtract One Gateway platform has been selected to modernize weapons detection and entry screening across a network of pharmaceutical manufacturing and distribution facilities. Initial deployments, valued at approximately $500,000, are already underway in California, Arizona, and Ohio, with additional sites scheduled for installation throughout this year and next.
The contract marks Xtract One’s entry into a potentially lucrative new market segment. Pharmaceutical and life sciences facilities have historically relied on conventional metal detectors that can create bottlenecks while generating elevated false-positive rates. Xtract One’s Gateway platform aims to address these shortcomings through advanced threat detection capabilities that can distinguish everyday items such as laptops, cell phones, notebooks, keys, and water bottles from genuine security risks.
This improved accuracy minimizes manual searches, enhances throughput, and creates a more efficient experience for employees and visitors. According to the company, Gateway can process individuals up to four times faster than traditional screening systems.
Importantly, management views this deployment as only the first phase of a broader multi-site rollout. With the pharmaceutical manufacturing industry representing a large addressable market, successful implementation could lead to additional deployments across numerous facilities. The company’s ability to integrate with existing security and camera systems may further strengthen its competitive position as organizations seek modern, low-friction security solutions.
For investors, the announcement demonstrates Xtract One’s ability to expand beyond its established markets and secure new enterprise customers in industries where security, operational efficiency, and employee experience are increasingly important priorities.
Clear!
Healthcare remains one of the most dynamic sectors in the market, and recent developments from MediPharm Labs, Oncolytics Biotech, and Xtract One Technologies demonstrate the wide variety of opportunities available to investors. From breakthrough dementia treatments and innovative cancer immunotherapies to advanced security solutions supporting pharmaceutical operations, each company is pursuing a different path toward long-term growth.
As always, investors should look beyond headlines and conduct thorough due diligence. Reviewing clinical data, understanding regulatory pathways, evaluating competitive positioning, and assessing balance-sheet strength can help separate genuine opportunities from temporary market excitement. By staying informed on companies making news and monitoring the milestones that matter most, investors can help ensure their portfolios remain as current and well-positioned as the rapidly evolving healthcare sector itself.
Get “Buzz on the Bullboards” delivered to your inbox every other Thursday!
Buzz on the Bullboards | Sign Up HereFor previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stocks on Stockhouse’s stock forums and message boards.